Navigation Links
LasikPlus® Research Reveals Excellent Results From Modern LASIK
Date:3/30/2011

CINCINNATI, March 30, 2011 /PRNewswire/ -- LasikPlus® surgeon Dr. Lewis Groden presented results from a first-of-its-kind, comparative study at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium revealing that LASIK procedures performed with modern excimer laser technology produce excellent results and very high patient satisfaction rates.

Each LCA-Vision (Nasdaq: LCAV) LasikPlus® vision center currently offers patients a choice of multiple state-of-the-art LASIK excimer platforms."Every day we witness life-transforming outcomes from this procedure and, as a company, we set out to determine scientifically whether technological advancements are producing outcomes that are as good as we believe," said Dr. Groden, surgeon at the Tampa LasikPlus® vision center and Director of Cornea Service for the University of South Florida Department of Ophthalmology.

The study included an analysis of 180 procedures performed on 90 patients, who were treated between October 20 and December 19, 2008. Three months post-operatively, 89 percent of these patients had uncorrected visual acuity of 20/20 or better, and 93 percent of these patients strongly agreed with the statement, "My vision is excellent."

LasikPlus®, in conjunction with industry collaborators, conducted the randomized study of the different state-of-the-art excimer laser technologies at three LasikPlus® vision centers. Independent calibration of the equipment was performed on each procedure day, visual acuity was determined by use of standardized vision charts and all 90 patients participated in follow-up interviews three months following their procedure. The data was analyzed by the independent research firm.

"After conducting this study at FDA standards, we concluded that we deliver the highest quality care with results equal to any technology in use today. Further, customer satisfaction rates were very high, validating our internal LasikPlus® surveys.  In fact, 95 percent of our patients would recommend LasikPlus® to a friend or co-worker according to our most recent monthly survey," added Dr. Groden.

"We're thrilled to now be able to offer our patients even greater confidence by showing independent research that verifies the quality of procedures performed on these modern platforms," he added. "Excimer technology has come a long way since FDA approval of photorefractive keratectomy in late 1995."

For more information about the ASCRS Symposium or the research, visit http://www.ascrs.org/11am/index.cfm.

About LCA-Vision/LasikPlus®LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, operates 54 LasikPlus® fixed-site laser vision correction centers in 26 states and 41 markets in the United States. Since the FDA approved photorefractive keratectomy in late 1995, we have performed nearly 1.2 million laser vision correction procedures at our vision centers.

LasikPlus® is partnering with the Wounded Warrior Project and the Fisher House Foundation to provide free LASIK services to wounded American veterans and their caregivers. To date, this partnership has led to the corrective surgery for nearly 100 wounded warriors and caregivers—putting their lives back in focus. For additional company information, please visit www.lasikplus.com.Contacts:Jennifer Riegert513-271-7222 x 22 (Office)513-309-2920 (Cell)jriegert@wordsworthweb.com
'/>"/>

SOURCE LCA-Vision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stanford researchers use river water and salty ocean water to generate electricity
2. Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
3. Sigma® Life Science Joins AMDeCs Vendor Partnership Program, Further Enhancing Value to Academic Medical Research Centers
4. Tibotec Advances Global Clinical Research Program for TMC435 in HCV; Will Present Four Abstracts Evaluating Safety and Efficacy at EASL
5. UBC researchers develop new model to predict the optical properties of nano-structures
6. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
7. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
8. Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
9. Leaders in Stem Cell Research and Discovery to Share Americas Most Distinguished Prize in Medicine
10. Trapping a rainbow: Lehigh researchers slow broadband light waves with nanoplasmonic structures
11. Rutgers researchers identify materials that may deliver more bounce
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017 Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... to participate in its previously announced rights offering ... shares of common stock and Series C Convertible ... listed warrants. As previously announced, ...
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
Breaking Biology Technology:
(Date:2/27/2017)... --  Strategic Cyber Ventures , the industry,s first cybersecurity ... million investment in  Polarity , the first commercial human ... based and is led by cybersecurity veterans Tom ... Gula , also a longtime cybersecurity veteran and founder ... A round of funding. This new funding will be ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
Breaking Biology News(10 mins):